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Abstract
Introduction: In 2014 the Joint United Nations Programme on HIV/AIDS defined the ambitious 909090 targets for 2020, in
which 90% of people living with HIV must be diagnosed, 90% of those diagnosed should be on sustained therapy and 90% of
those on therapy should have an undetectable viral load. Children are considered to be a key focus population for these targets.
This review will highlight key components of the epidemiology, prevention and treatment of tuberculosis (TB) in HIV-infected
children in the era of increasing access to antiretroviral therapy (ART) and their relation to the 909090 targets.
Discussion: The majority of HIV-infected children live in countries with a high burden of TB. In settings with a high burden of
both diseases such as in sub-Saharan Africa, up to 57% of children diagnosed with and treated for TB are HIV-infected. TB results
in substantial morbidity and mortality in HIV-infected children, so preventing TB and optimizing its treatment in HIV-infected
children will be important to ensuring good long-term outcomes. Prevention of TB can be achieved by increasing access to
ART to both children and adults, and appropriate provision of isoniazid preventative therapy. Co-treatment of HIV and TB is
complicated by drug-drug interactions particularly due to the use of rifampicin; these may compromise virologic outcomes if
appropriate corrective actions are not taken. There remain substantial operational challenges, and improved integration of
paediatric TB and HIV services, including with antenatal and routine under-five care, is an important priority.
Conclusions: TB may be an important barrier to achievement of the 909090 targets, but specific attention to TB care in
HIV-infected children may provide important opportunities to enhance the care of both TB and HIV in children.
Keywords: tuberculosis; HIV; AIDS; children; infant; treatment; epidemiology; 90-90-90 target.
Received 20 April 2015; Revised 9 September 2015; Accepted 25 September 2015; Published 2 December 2015
Copyright:– 2015 Rabie H et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution
3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Introduction
An estimated 240,000 children were newly infected with HIV
in 2013 despite scale-up of prevention of mother-to-child
transmission (PMTCT), which resulted in a 40% reduction in
perinatal transmission of HIV in 2011 compared to 2009 [1].
The majority of HIV-infected children (630,300) live in Africa,
followed by Asia (54,100) and Latin America (26,400) [1].
Although 13.6 million HIV-infected people accessed combina-
tion antiretroviral therapy (ART) in 2014, this represents only
38% of adults and 24% of children with HIV. The regions with
the lowest access to therapy are also in Africa (20 to 24%)
and Asia (22 to 32%) [1]. In order to address these ongoing
critical gaps in HIV care, the Joint United Nations Programme
on HIV/AIDS defined the ambitious 909090 targets to be
achieved by 2020: 90% of persons living with HIV must be
diagnosed, 90% of those diagnosed should be on sustained
therapy and 90% of those on therapy should have an un-
detectable viral load. These targets were designed to stimu-
late rapid scale-up of sustainable and high quality HIV care,
in order to prevent new HIV infections and to reduce HIV-
associated morbidity and mortality. Adolescents and children
were identified as key focus populations [2].
Tuberculosis (TB) remains a major cause of disease globally,
with 9 million incident cases; 13% of these cases were
HIV-infected. There were 1.5 million TB deaths in 2013, of
which 360,000 were in HIV-infected persons. Although Asian
countries (particularly China and India) account for the highest
numbers of TB cases, all the countries with a TB incidence of
more than 500 cases per 100,000 population are in Africa [3].
Models estimate that in 2010 there were 650,000 cases of
TB disease in children andmanymore with latent infection [4].
In settings with a high burden of both diseases up to 56% of
children treated for TB had HIV [5].
Given the close overlap of the TB and HIV epidemics, suc-
cessful achievement of the 909090 targets must specifi-
cally consider TB and its impact on HIV diagnosis, retention in
care and attaining virologic suppression.
In this paper we discuss key aspects of the care of TB in
HIV-infected children, highlighting threats and opportunities
on the road to 909090. We will discuss the epidemiology
of TB-HIV co-infection, calling attention to the ongoing close
interactions of these two diseases, as well as recent advances
in the prevention of TB in HIV-infected children. We will des-
cribe developments in the treatment of TB and HIV and the
implications of these for the reduction of morbidity and
mortality in TB-HIV co-infected children.We will also focus on
the emerging threat of drug-resistant TB.
Rabie H et al. Journal of the International AIDS Society 2015, 18(Suppl 6):20236
http://www.jiasociety.org/index.php/jias/article/view/20236 | http://dx.doi.org/10.7448/IAS.18.7.20236
1
The epidemiology of TB-HIV co-infection
As described above, the TB and HIV epidemics have subs-
tantial overlap in their epidemiology. It is clear that Africa
(particularly sub-Saharan Africa), South East Asia (Thailand
and India) and Latin America carry the biggest burden of TB
and HIV [1,6]. This has impacted children directly and through
its impact on women of childbearing age. The HIV epidemic
disproportionately increased the burden of TB in women of
childbearing age [7]. One-third of TB deaths in women are in
HIV-infected women [6]. Data from India confirms that where
TB occurs in HIV-infected pregnant women, the infant is not
only at risk for TB, but has a threefold higher risk of HIV
acquisition and a fourfold increase in mortality [810].
The risk of TB in HIV-infected children
HIV-infected and HIV-exposed infants are highly TB exposed
in their households and local communities. In a South African
trial of isoniazid preventive therapy (IPT), 10% of HIV-
exposed infants had contact with a potential case of TB by
14 weeks of age [11].
In addition to frequent TB exposure, other conditions, in-
cluding advanced immune suppression, poor nutritional status
(stunting, wasting and reduced mid-upper arm circumference)
and anaemia are associated with increased risk of TB in HIV-
infected children [12]. The proportion of children with TB that
are HIV co-infected varies from 5.8 to 56% depending on the
setting [5].
Among South African infants with limited access to ART, up
to 1595 cases per 100,000 population have been reported;
this is more than 24 times the rate reported at the same time
for HIV-uninfected South African infants [13]. The risk in-
creases after six months of age in the absence of ART, with
incidence rates of 6.2 to 18.1 cases per 100 person-years
(age B6 months) and 9.4 to 46.3 cases per 100 person-years
(age ]6 months) reported in East Africa [14]. In other HIV-
infected African children with poor access to ART, high risk of
TB is also reported (more than 17 TB cases per 100 person-
years) [1518]. A review study of African post-mortem studies
reports pulmonary TB in 8.3% of HIV-infected children [19].
In low-burden settings, the risk of TB in HIV-infected
children is much less; however TB still occurs. Among children
attending HIV services in the United Kingdom (between 1991
and 2006) and New York City (between 1989 and 1995) 3 to
5.5% had a diagnosis of TB at some point [20,21].
TB prevention in HIV-infected children
TB co-infection negatively affects outcomes for HIV-infected
patients, and there are challenges with TB diagnosis and
co-treatment in HIV-infected children. These factors may all
impact negatively on achieving 90% retention on ART and
90% virologic suppression; hence strategies to prevent TB in
HIV-infected children are a priority for achieving the 909090
targets.
Antiretroviral therapy for HIV-infected children and adults
Increasing access to ART in paediatric cohorts decreases
confirmed and probable TB. In the Children with HIV Early
Antiretroviral Therapy (CHER) study, South African infants
with deferred ART had 20 cases of TB per 100 person-years,
compared to 8.3 cases per 100 person years in children
receiving early ART [17]. Up to 33% of infants starting ART at
a median age of eight months are already on TB therapy,
indicating early infancy as a particular risk period and high-
lighting the importance of early initiation of ART [22]. A
similar reduction in risk of TB in older children receiving
ART has also been demonstrated in diverse settings in Africa,
Asia and Latin America [15,16,18,2228].
The first three months after initiation of ART represent
a very high-risk period for hospitalization and death [29]. In
addition, there is a substantial initial increase in the risk of
TB, likely representing undetected TB, TB exposure at ART
initiation or unmasking TB immune reconstitution inflamma-
tory syndrome (IRIS) [27,3033].
With increasing access to ART in adults, the risk of TB
declines in adults as well as in HIV-infected and -uninfected
children. In Johannesburg, South Africa, ART access in adults
increased from 21.5% in 2005 to 68.2% in 2009 of those
requiring ART. During the same period, TB in HIV-infected
children declined from 1566.3 to 460.7 per 100,000 and in
HIV-uninfected children from 18.7 to 11.0 per 100,000 [34].
If ART expands to cover 80% of adults living with HIV, TB
incidence among all adults is projected to decline by 28 to
37% [35]. A reduction of adult TB cases, particularly among
HIV-infected adults, would likely have an important impact
on the risk of TB exposure, infection and disease among HIV-
infected children.
Despite these clear benefits of ART, the risk of TB remains
high in HIV-infected infants and children even when on ART.
In South African infants with a 98% uptake of ART, those that
were HIV-infected had a burden of 121 cases per 1000 years
compared to 41 cases per 1000 child-years in HIV-exposed
uninfected infants [36]. This highlights the importance
of a multi-pronged strategy to address TB in HIV-infected
children.
BCG vaccination
Although Bacille Calmette Gue´rin (BCG), a live attenuated
Mycobacterium bovis strain, is protective against dissemi-
nated TB, including meningitis in young children, it is less
effective at preventing pulmonary TB [37]. BCG itself poses a
risk to HIV-infected children, particularly those with severe
immunosuppression and delayed initiation of ART. Dissemi-
nated BCG, a serious and potentially life-threatening com-
plication of BCG vaccination, occurs in an estimated 992
(95% CI: 567 to 1495) per 100,000 HIV-infected infants [38].
In addition, infants initiating ART may develop IRIS related
to BCG [39]. Given these concerns, the WHO recommended
that BCG not be administered to persons who are confirmed
HIV-infection [40]. As BCG is given at birth to healthy infants,
this recommendation is problematic in settings where birth
HIV DNA PCR is not routine, particularly as these are often
the same settings with a high TB burden. Early infant diag-
nosis of HIV and early ART mitigates the risk of disseminated
BCG and IRIS [41]. In a prospective study of 451 HIV-infected
infants receiving early ART, none developed disseminated
BCG disease; although BCG IRIS remained a problem, the risk
was reduced threefold with early access to ART [39]. Rather
than altering BCG vaccine delivery or managing IRIS, most
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countries are focusing on prevention of HIV transmission to
children and access to ART [42].
Isoniazid preventative therapy
Young age is an important risk factor for the development of
TB disease after infection [43]. Treating latentMycobacterium
tuberculosis infection with isoniazid (INH) prevents disease
[44,45]. Therefore the WHO recommends the provision of IPT
for a minimum of six months to all children B5 years of age,
and HIV-infected children of any age, with a documented
infectious TB source case; this is an integral component of TB
prevention in HIV-infected children [6].
Studies of pre-exposure and longer-term IPT in HIV-infected
children have yielded conflicting evidence. In the only true
pre-exposure prevention trial (IMPAACT P1041), 548 HIV-
infected and 804 HIV-exposed uninfected infants between
three and four months of age without TB exposure were
randomized to INH versus placebo for 96 weeks with follow-
up for another 96 weeks. The pre-exposure prevention did not
reduce the TB incidence in either HIV-exposed-uninfected or
HIV-infected infants [36]. An earlier placebo controlled study
of IPT for all HIV-infected children enrolled older children with
delayed access to ART, including those with prior TB or TB
exposure. This study showed a significant reduction in TB and
all-cause mortality (9.9 and 16% in the placebo arm vs. 3.8
and 8% in the IPT arm). Subsequent analysis of this cohort
illustrated that combining IPT with ART was more effective
than either strategy alone to prevent TB [16,46]. In 2014, the
WHO recommended routine pre-exposure IPT for six months
in all HIV-infected children older than 12 months without
evidence of TB disease [6]. Children with suggestive symp-
toms (poor weight gain, fever and current cough) or with a
history of TB exposure should be investigated for TB prior to
IPT initiation. Diagnostic challenges in HIV-infected children
remain a reality, especially if there is no TB contact but sug-
gestive symptoms. The WHO guidelines also recommend that
children treated for TB with a good response should receive
six months of INH postTB treatment completion; however,
there is little evidence for this recommendation.
There are substantial challenges in IPT implementation,
including health system weakness and lack of availability
of child-friendly INH formulations. Missed opportunities for
chemoprophylaxis are well documented. A community-based
study from South Africa found that only 21% of eligible
children received IPT and that the lack of specific tools to
ensure implementation possibly contributed to low uptake
[47]. Poor adherence to IPT remains a challenge [48]. Health
care worker training and introduction of specific documenta-
tion such as cards and registers, as well as contact tracing,
increased uptake of IPT from 16 to 61% [49]. Integration of
TB and HIV services may also increase IPT completion [50].
In HIV-uninfected children, adherence is improved by using
rifamycins, which require shorter courses [51]. This is not
an option for HIV-infected children on ART or HIV-exposed
infants on extended nevirapine (NVP) prophylaxis for HIV pre-
vention, as rifamycins have important drug-drug interactions
with a number of antiretrovirals. Twelve doses of rifapentine-
INH, recently shown to be effective in HIV-uninfected children,
was not studied in HIV-infected children [52].
There is no published data in HIV-infected children on the
benefit of tuberculin skin testing or other tests of infection,
such as the interferon gamma release assays, to help target
pre-exposure IPT. Data in HIV-infected adults suggests that
TST-positive adults benefit the most from IPT [53]. No TB
prevention studies have specifically targeted adolescents.
However, the risk of TB increases during adolescence [43],
and HIV-infected adolescents with TB exposure or infection
would potentially benefit considerably from IPT. Drug resis-
tance in TB source cases may be a major factor in children
failing IPT. In the IMPAACT P1041 trial, children developing
culture-confirmed TB on INH did not have INH mono-
resistance, but rather multidrug-resistant (MDR) TB [54].
Obtaining a thorough history of the potential contacts prior
to IPT initiation is important; if a child on IPT develops TB,
the contacts should be reviewed again for resistance and
clinically relevant specimens should be taken for culture and
susceptibility testing prior to starting TB treatment.
Other TB prevention opportunities
There are a number of other additional opportunities for
preventing TB in HIV-infected children. Temporal associations
between TB, influenza and pneumococcal disease in children
suggest a complex interaction between these infections.
An increase in TB diagnoses following approximately three
months after an influenza epidemic in a high burden set-
ting suggests a potential role for the influenza vaccine in
reducing the TB burden [55]. A study of TB after introduction
of conjugated pneumococcal vaccine showed that culture-
confirmed TB was 47% less in vaccinated compared to un-
vaccinated HIV-infected children [56]. Cotrimoxazole appears
to have anti-mycobacterial activity [57] and conflicting evi-
dence suggests cotrimoxazole prophylaxis may reduce in-
cident TB in HIV-infected adults [58,59]. In a trial of 758
HIV-infected children on ART randomized to prolonged cotri-
moxazole despite immune reconstitution, there were fewer
incident cases of TB, although numbers were small [60].
These strategies, in addition to reducing their targeted dis-
ease, may have the benefit of reducing TB, adding to the
urgency of their implementation in HIV-infected children. In
the absence of a highly effective TB vaccine, a multi-pronged
approach to TB prevention is likely to be the most successful
and is important in enabling achievement of the 909090
targets.
Outcomes among TB-HIV co-infected children
Prior to wide access to ART, high mortality of co-infected
children was reported. A study from South Africa documen-
ted a 10 times higher mortality in TB-HIV co-infected children
than in HIV-uninfected children with TB [12]. Children
with TB-HIV co-infection who died often had additional
pulmonary infections on post-mortem [61]. With access to
ART, better outcomes are reported, particularly for children
who develop TB while on ART for more than six months;
however, mortality does occur especially in the first two
months of ART. A retrospective observational study from
South Africa reported 10% mortality in TB-HIV co-infected
children less than two years of age [18,22]. Deaths may be
due to TB, other HIV complications or IRIS. The effect of TB
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co-infection on mortality thus affects the achievement of
90% retention on ART.
Virologic outcomes in children co-treated with rifampicin
Concomitant TB therapy may be a significant risk factor for
virologic failure in children who are co-treated, impacting
the target of 90% of children on ART being virologically
suppressed. Viral load is not available in all settings where
there is a high TB burden. In settings where the protease
inhibitor (PI) lopinavir/ritonavir (4:1) LPV/r is the preferred
initial therapy in childrenB3 years and super-boosting is
used, high levels of viral suppression are reported for children,
regardless of co-treatment. However the rates of suppression
at 6 and 12 months are lower than those of children not
requiring co-treatment [6264]. Studies of children failing
LPV-based regimens have shown accumulation of PI mutations
in 10% of children tested a median of 21 months after
initiation of therapy [65]. Although concurrent TB therapymay
be a risk factor for virologic failure, it was not necessarily a
risk factor for LPV resistance [67]. A likely explanation is the
robust resistance profile of LPV; however great care should
be taken to ensure dosing accuracy and appropriate addition
of ritonavir (RTV). RTV at full dose should not be used as
therapy, as it is associated with the highest risk of failure and
PI resistance [62,66].
No difference in virologic suppression has been seen with
efavirenz (EFV)-based therapies at month 12 [64]. There is
limited data on the routine virologic outcomes of children
treated with NVP. However, poorer virologic outcomes are
reported in several cohort studies when compared to EFV,
regardless of TB therapy [67,68].
Treatment
Optimizing the co-treatment of TB and HIV is important to
ensuring the targeted 90% treatment success in HIV-infected
children.
In low resource settings, TB treatment initiation is as fre-
quent a cause of ART regimen changes as adverse effects [69].
When choosing an ART regimen, apart from drug interactions,
clinicians should also consider prior ART, available drugs and
formulations, age and weight. For children on ART, clinicians
must also consider duration on therapy, adherence to therapy
and the probability of therapeutic failure.
First-line TB medications and drug-susceptible TB
In 2010, the WHO recommended higher doses of the first-
line anti-TB drugs in all children [70]. This recommendation
was based on an extensive review of evidence demonstrating
low exposure with the previously recommended doses. These
changes introduced practical challenges, as the ratio of RMP,
INH and pyrazinamide (PZA) in the existing paediatric fixed-
dose combination (FDC) formulations does not allow for easy
dosing within the new recommendations [71].
Among 20 children younger than two years receiving the
newly recommended doses of INH, RMP and PZA, nearly
all children had maximum serum concentrations of these
medications above target levels. HIV-infected children in this
study (n5) had a significantly lower Cmax and Tmax on PZA
35 mg/kg, but no difference in total exposure; the small
sample size may have limited the ability to detect other
differences [72]. In 31 South African children younger than
10 years, the majority receiving the new WHO-recommended
doses of the first-line TB medications, two-hour target con-
centrations were attained for RMP in only 2/31 (6%), for INH
in 20/31 (65%), for PZA in 17/31 (55%) and for ethambutol
(EMB) in 2/13 (15%); HIV infection (n7 children) was
associated with a low two-hour INH concentration [73].
It is not clear whether the reduced TB drug concentrations
reported in these studies are related to interactions with ART
or the direct effects of HIV infection; neither study clearly
describes the ART regimens in the included HIV-infected
children. Studies of the first-line TB medications in children
are ongoing (NCT01637558 and NCT01687504).
Despite limited evidence, the WHO recommends the
addition of EMB to the intensive phase of TB treatment in
children with HIV, extensive disease or in settings with a high
prevalence of INH resistance [6]. The rationale for this is that
EMB may protect against the acquisition of RMP resistance in
children with existing INH resistance; acquired RMP resis-
tance in children has been described, although the actual
risk is not known [74]. Additional data on the benefit, risk
and programmatic implications of this recommendation
for HIV-infected children is needed. An extensive review of
the literature identified very few reports of EMB-associated
ophthalmologic toxicity in children [75]. Recently in a study
of a small number of children treated with EMB, newer tech-
nology identified reversible ophthalmological complications
attributed to EMB. EMB should continue to be used when
indicated, but this risk deserves further evaluation [76].
Second-line TB medications
Despite common use there is little data on the pharmaco-
kinetics of second-line TB medications in children [77]. The
currently recommended doses of ofloxacin, levofloxacin and
moxifloxacin result in drug exposures considerably lower
than in adults, and moxifloxacin exposure is significantly
lower in HIV-infected compared to HIV-uninfected children
[78,79]. It is not clear if this is due to poor absorption or a
potential drug interaction with RTV [79,80]. In HIV-infected
adults, co-treatment with EFV results in a more than 30%
reduction in para-aminosalicylic acid exposure [81]. There are
no recommendations to alter doses of any of the second-line
TB medications or ART in co-treated children, but additional
data is urgently needed.
HIV infection may be a risk factor for adverse events among
children treated for MDR-TB. A higher risk of ethionamide-
induced hypothyroidism has been shown compared to HIV-
uninfected children [82]. Linezolid, used in children with
extensively drug-resistant TB, may have additive adverse
effects with nucleoside reverse transcriptase inhibitors (NRTIs)
due to mitochondrial protein synthesis inhibition and should
be used with caution in HIV-infected children [83].
Novel TB medications
Two novel TB medications, the ATP-synthase inhibitor beda-
quiline and the nitroimidazole delamanid are increasingly
used in adults [84,85]. Phase 1 and 2 studies of delamanid
in children (NCT01856634, NCT01859923) have begun enrol-
ment, and studies of bedaquiline in children are planned.
Current studies exclude HIV-infected children but future
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studies will include them. Metabolism of delamanid is par-
tially mediated by the cytochrome p450 (CYP) 3A4 enzyme,
but healthy volunteer studies indicated no clinically signifi-
cant drug-drug interactions with ART [85]. Bedaquiline is
metabolized by CYP3A4 isoenzyme; co-administration with
the CYP3A4 inducer EFV reduces exposures of bedaquiline and
its main metabolite, M2, by roughly 50%. Co-administration
with lopinavir, an inhibitor of CYP3A4, reduces clearance by
35% for bedaquiline and by 58% for M2, resulting in two- to
threefold higher exposures of bedaquiline and M2. There is no
clinically significant interaction between bedaquiline and NVP
[8688]. Data on the pharmacokinetics and safety of bedaqui-
line and delamanid in HIV-infected children will be important
to ensure these medications are accessible and able to be
safely used in these children.
Deciding on the appropriate ART in children with TB
Drug-drug interactions between TB medication, especially
rifamycins, and ART are a major concern, as they may in-
fluence the virologic outcomes of co-treated patients, lead-
ing to HIV treatment failure and increasing the risk of ART
resistance, potentially limiting future therapy. The drug in-
teractions between NRTIs and RMP are not considered
clinically significant; however there are significant interac-
tions with non-nucleoside reverse transcriptase inhibitors
(NNRTIs), PI and integrase inhibitors. For some of these
interactions, there is no paediatric data.
Protease inhibitors
LPV/r is superior to NVP in young children regardless of
previous NVP or EFV exposure through PMTCT [89,90]. LPV/r is
now recommended as first line in most children B3 years of
age [91]. Given its more prominent role, drug-drug interac-
tions with TBmedications are important. LPV/r concentrations
are reduced by RMP CYP3A4 induction and through changes in
the p-glycoprotein expression [92]. Adding RTV to alter the
ratio from 1:4 to 1:1 (so called super-boosting) was shown to
overcome this RMP effect in a study of 15 children (median
age 16 months, median weight 8.6 kg). The median Cmax and
AUC012 were lower than in controls, but the Cmin (the target
for efficacy) was greater than the minimum recommended.
Children tolerated the strategy and two cases had mild alanine
transaminase elevation that did not require therapy interrup-
tion [93]. Preliminary data from an ongoing study of a large
cohort of young TB-HIV co-treated South Africans receiving
super-boosting (NCT02348177) confirms this finding [94].
In adults, giving double the dose of LPV/r was found to have
acceptable pharmacokinetic and less toxicity [95]. However,
of 20 children (median weight 9.1 kg, median age 1.2 years)
receiving double-dose LPV/r (460/115 mg/m2 twice), 80%
did not achieve a target morning trough of 1 mg/L [96].
Explanations include characteristics of the formulation as
well as drug absorption and metabolism. A modelling study
suggests that overcoming the interaction with RMP using the
LPV/r 4:1 solution with twice daily administration will require
such high doses that there may be adverse events, whereas
an eight-hourly dosing regimen may overcome the drug inter-
action; a study of this is ongoing [97]. The individual RTV
formulation requires refrigeration for storage and has a short
shelf life, complicating its use in resource-limited settings,
and when only used for super-boosting may be a challenge for
supply chains to maintain continuous widespread avail-
ability. Additionally, it is poorly palatable and may be pro-
blematic to administer to children. In settings increasingly
utilizing task-shifting and relying on nurses for ART provision,
these complicated drug-drug interactions between LPV/r and
TB medication may be a barrier to a super-boosting strategy.
The optimal approach to ART in TB-HIV co-infected children
may need to be considered by each high-burden country
depending on these contextual issues, and improved options
are needed. In order to facilitate access to LPV/r, mini-tablets
were developed and are now licensed by FDA.
Rifabutin, which does not affect PI concentrations, is also
problematic. Rifabutin is metabolized by CYP3A4 and dose
adjustments of rifabutin are needed if co-treating with PIs;
however pharmacokinetic data in children is limited. In six
children treated with rifabutin 5 mg/kg three times per week
and with LPV/r, severe transient neutropenia and insufficient
rifabutin exposure was observed [98]. Using rifabutin in a
public health programme is currently not possible due to lack
of data in co-treated children, complex two-way interactions,
cost and lack of an FDC.
There is a lack of paediatric data for boosted atazanavir
(ATV) and darunavir (DRV), which also both interact with
RMP. In adult volunteers, double doses of ATV with RMP did
not correct the ATV exposure but did not cause substantial
toxicity [99]. For DRV, modelling of adult data suggests that
dose increases of DRV and RTV (800/100 mg and 1200/150
mg twice a day) both may overcome the RMP induction;
the usual adult dose is 800/100 mg daily for naı¨ve patients
older than 12 years of age [100]. This dose increase may,
however, cause adverse effects and there are no published
data studying this approach. The interaction and optimal PI
treatment strategy in children with TB is a critical area for
future research given the importance of these medications in
ART regimens.
Non-nucleoside reverse transcriptase inhibitors
EFV is used in older children and is superior to NVP [67].
Recent data suggests that no adjustment of EFV dose is
required when RMP is used [101,102]. Previously a lack of
data in dosing prevented EFV use in children younger than
three years. Though it is now licensed for this age, experts
recommend CYP2B6 genotype prior to EFV initiation in this
age group [103]. Using EFV in this age group with prior NNRTI
exposure has not been studied and data on co-treatment
with RMP-containing TB regimens are not available.
NVP is a commonly used NNRTI in low resource settings,
where it is incorporated in easy-to-use and well-tolerated
FDCs. There are reports of adequate exposure in RMP co-
treatment but larger co-treatment studies found significant
under-dosing even if NVP was given at more than the standard
recommended dose [104106]. The period of initiating NVP-
containing ART using daily NVP for 14 days may be particularly
risky in children who are also on RMP, as NVP concentrations
may be low; avoiding the induction dosing in all children
younger than two years of age has been suggested [107].
Where NVP use cannot be avoided in TB co-treated children,
a dose of 200 mg/m2/dose twice daily should be used [91].
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Switching children with TB from NVP to EFV should be
considered wherever possible. Lastly, children taking NVP as
PMTCT, where mothers are on RMP or where the infants
require RMP-TB therapy, may have low NVP concentrations
[108]. These low concentrations may reduce the efficacy of
NVP in preventing HIV.
Switching suppressed children from LPV/r to EFV is a stra-
tegy studied in children without TB [109]. Although prospec-
tive studies have not been performed, a switch to EFV can be
considered if children develop TB. If at all possible, viral load
monitoring should be done to detect early failure, in which
case further action must be taken.
Etravirine is not typically available in low resource settings
and is not approved for use in children less than six years of
age. There are no adult studies assessing the interaction of
RMP and etravirine, with the exception of case reports, which
confirm a significant reduction in plasma levels, which did
not impact virologic suppression [110].
Based on results of the Antiretroviral Research for Watoto
(ARROW) study, the WHO recommends triple NRTIs as a
preferred strategy in children age B3 years requiring RMP
co-treatment. In ARROW, three NRTIs were studied as an
intensive induction and a maintenance strategy when com-
bined with NNRTIs. After 48 weeks of initial therapy that
contained a NNRTI children were randomized to a three-drug
NRTI maintenance regimen or to remain on conventional
therapy. Fifty-nine of the 1143 children required a drug
alteration for TB that included stopping or replacing NVP.
Children on EFV did not require drug switch. Triple NRTI was
effective at 36 weeks, but not at 144 weeks. The advantage of
this strategy is that, although viral suppression is inferior, the
risk of progressive NNRTI and PI resistance was avoided and
complicated drug-drug interactions and logistic complications
were easier to manage [69]. Where PIs are available, limited
NRTI resistance may not compromise future suppression.
However, this strategy could be problematic in very ill children
where viral control and immune recovery is essential to
improve the health of the child.
Integrase inhibitors and other issues
Integrase inhibitors are an increasingly important class of
ART, particularly as a key component of third-line regimens.
Raltegravir and dolutegravir are not metabolized by the CYP
P450 enzymes but are metabolized through the liver by
uridine 5-diphospho (UDP)-glucuro-nosyltransferase 1A1,
an enzyme that is also induced by RMP. Healthy volunteer
studies showed a significant reduction in raltegravir exposure
with RMP co-treatment [111]. In a prospective study com-
paring standard and double-dose raltegravir with EFV in ART-
naı¨ve adults requiring RMP, no significant difference was
found in virologic suppression at 24 weeks between the
standard and double-dose raltegravir groups, with both
groups similar to the EFV group [111]. There is no published
data in children; however an ongoing study is assessing the
effective dosing, safety and tolerance of children co-treated
with raltegravir and RMP (NCT01751568).
Adult healthy volunteer studies assessing the effect of
RMP on dolutegravir suggest that doubling the dolutegravir
dose is needed if there is co-treatment with RMP [112].
Children needing third-line therapy and co-treatment with
RMP-containing TB therapy may benefit from a holding triple
NRTI strategy. This may be a good option if the children have
a preserved CD4 count and are clinically stable. Where chil-
dren require a suppressive regimen urgently, consideration
should be given to changing to a non-rifamycin-containing
TB regimen. Rifabutin also has less substantial interactions,
but dose adjustment of rifabutin and ARTmay still be needed.
Rifapentine is not recommended, as there may be a risk of
RMP-monoresistant TB developing [113]. Fluoroquinolone-
based TB regimens could be considered, but have not been
prospectively studied in this context
Approach to timing of ART initiation
The timing of ART initiation in adults with TB has been
extensively studied. Delaying therapy in adults with a CD4
count of B200 cells/mL has been associated with poor viro-
logic and clinical outcomes [112]. The timing of ART initiation
in children with TB has not been studied prospectively.
In observational paediatric cohorts, delaying therapy for up
to two months was not associated with an increased risk of
mortality or poorer virologic response [114]. Whether longer
delay in older children and adolescents with good CD4 counts
and minimal TB disease is acceptable is not known.
TB meningitis (TBM) is an exception regardless of CD4
count, since clinical deterioration due to paradoxical IRIS can
be devastating. In the adult literature, IRIS is associated with
more disseminated forms of the disease and positive culture
in the cerebrospinal fluid. It is common practice to delay ART
four to six weeks in TBM [115]. Although there are fewer
data in children, case series confirm the high morbidity
associated with paradoxical IRIS [116]. There are no pro-
spective data in children and it is important to keep in mind
that the outcomes in patients with TBM are also determined
by the severity of meningitis. Only 20% of HIV-uninfected
children are neurologically normal after full TBM treatment
[117].
If children are already on ART, appropriate anti-TB therapy
should be started as soon as the appropriate diagnostic
testing has been performed. ART should be adapted and the
possibility of virologic and or immunological failure must be
considered and appropriately investigated.
Drug-resistant TB
MDR-TB (resistant to INH and RMP) is a growing health
threat with an estimated 480,000 cases occurring in 2013; 9%
of these cases also had additional resistance to a fluoro-
quinolone and/or a second-line injectable medication [3].
Despite limited data on the burden of MDR-TB in children,
a 2010 model estimates a burden of 32,000 cases. Children
typically have transmitted or primary MDR-TB. Among child-
hood MDR-TB cases in South Africa, HIV infection was
reported in 53.6, 77 and 22% in Johannesburg, Kwa-Zulu
Natal and Cape Town [118120]. HIV infection was indepen-
dently associated with prevalent TB disease among child
household contacts of adult MDR-TB cases and is associated
with poorer outcome in child MDR-TB household contacts on
MDR preventive therapy [121] HIV-infected children were
also older and had more severe disease [122]. A recent
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review of adults and children with HIV and MDR-TB showed
83.4% treatment success in children [123]. It is becoming
increasingly important to ensure that diagnostic, prevention
and treatment strategies for MDR-TB are developed for HIV-
infected children.
Operational issues
Initially TB and HIV services were introduced as vertical
programmes, but now strategies to integrate these services
and strengthen the linkage to antenatal care are essential to
improving diagnosis and access to care and treatment. HIV
testing remains the entry point for HIV care. Ensuring that
children diagnosed with TB are tested for HIV is absolutely
essential. Given the high risk of HIV co-infection in children
with TB in many settings, routine HIV testing of all children
receiving TB treatment is an important opportunity to in-
crease HIV diagnosis and thus achievement of 90% of HIV-
infected persons knowing their status.
The diagnosis of TB in all children remains challenging. A
study of paediatric ART programmes in diverse resource-
limited settings showed that, although sputum microscopy
and CXR were available in all programmes, they were only
used in 86 and 52% of TB diagnoses. Xpert MTB/RIF was only
used in 8% of TB diagnoses and mycobacterial culture in 17%.
Eighty-six percent of sites provided access to TB treatment,
but 30% never provided IPT to children [124]. Adult contact
tracing and access to IPT remains a vital component of care
in HIV-infected children regardless of the ART therapy.
This undertaking starts with taking the appropriate history
at each health care contact. HIV-infected children who have
defaulted care may be picked up and re-enter care at TB
services.
Screening of pregnant women for both HIV and TB may
improve access not only to PMTCT, but also to IPT. Integrating
TB services into antenatal care of HIV-infected women may
also be key to preventing TB in young infants [125]. In Table 1
we highlight the components of care that require linkage and
integration. Health care providers in all these settings need
competency in all these aspects. Health system strengthening
aimed at meeting the 909090 targets will need to consider
TB services and may have beneficial impacts for TB care in
children as well.
Conclusions
The TB and HIV epidemics remain closely interlinked and TB
is still an important opportunistic infection in HIV-infected
children, with substantial mortality and morbidity and with
co-treatment possibly affecting HIV outcomes. The growing
burden of drug-resistant TB poses new challenges. Increasing
ARTaccess has the potential to greatly impact the TB epidemic
in settings with high dual burden. The reduction in adult cases
will reduce TB infection to both HIV-infected and -uninfected
infants and children. Early ART in HIV-infected children will
further reduce the burden of TB in these children. The provision
of IPT should be strengthened, and innovative prevention
strategies such as influenza and pneumococcal vaccination and
continuing co-trimoxazole should be explored. Treating these
diseases simultaneously presents challenges with regards to
choosing the most appropriate regimens and ensuring that
medications are available in all settings and easy for children
to adhere to. There is a synergy between working towards the
909090 targets and improving TB diagnostic and treatment
programmes. Efforts to meet the 909090 targets for both
adults and children may well have a profound impact on the
burden of childhood TB, while improved prevention, diagnosis
and treatment of TB in co-infected children, as well as strength-
ening and integration of TB-HIV programmes, will be important
if the 909090 targets are to be achieved.
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Table 1. Components of care that require linkage and integration to deliver tuberculosis preventative and treatment services to
HIV-infected children
Tuberculosis services HIV services Antenatal care General healthcare/IMCI
Screen for TB contact and link to IPT ª ª
Trace contacts ª ª ª
Screen for TB ª ª ª
Diagnose TB ª ª ª ª
Diagnose HIV ª ª ª ª
Treat TB/link to TB care ª ª ª ª
Provide ART link to ART care ª ª ª
Adapt drug choices to accommodate rifamycin ª ª ª
Ensure adherence to all therapies ª ª ª
IMCI: Integrated Management of Childhood Illness; TB: tuberculosis; IPT: isoniazid preventative therapy; ART: antiretroviral therapy.
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